Claim OwnershipPharma and BioTech Daily
Subscribed: 106Played: 1,304
Subscribe
© 2025 Pharma and BioTech Daily
Description
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
148 Episodes
Reverse
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of pivotal events shaping the landscape of drug development and patient care. The interplay between scientific advancements, regulatory shifts, and strategic partnerships is setting the stage for significant transformations within the industry.A highlight of recent developments is the legal challenge faced by Merck & Co. regardin...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, the landscape of the pharmaceutical and biotech industries is marked by groundbreaking scientific advancements, regulatory shifts, and strategic collaborations that promise to reshape patient care and drug development significantly.A controversy has emerged in the wake of proposed changes to U.S. vaccine regulations by Dr. Vinay Prasad, a senior FDA offic...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal events and breakthroughs shaping the future of this dynamic industry.The pharmaceutical and biotech sectors are experiencing a wave of significant advancements, regulatory shifts, and strategic maneuvers. Recently, Bristol Myers Squibb faced a delay in their Alzheimer's psychosis treatment, Cobenfy, due to site irregu...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant shifts and advancements shaping these dynamic industries.Let's begin with Imvax, a biotechnology company that's making waves with its brain cancer cell therapy. Despite not hitting the primary endpoint in their Phase 2b trial, Imvax has taken the bold step of submitting their therapy to the FDA. This decision is r...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore the latest advances and strategic moves shaping the industry, providing you with insights into how these developments might influence drug development and patient care.The pharmaceutical and biotech sectors are currently experiencing a wave of transformative changes. A significant development is the trade agreement between the United States ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we're diving into a fascinating exploration of how the biotechnology industry might evolve by adopting a model inspired by Japan's keiretsu system. This concept, known as "biokeiretsu," is being proposed as a transformative strategy to address the structural inefficiencies that hinder the growth of biotech ventures today.To understand the potential impact ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering f...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve deep into a series of transformative events that underscore the dynamic nature of our industry, where scientific innovation meets regulatory evolution and market adaptation.We begin with significant regulatory news from Medicare, which recently announced price reductions for 15 prescription drugs, including Novo Nordisk's semaglutide products, Oz...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a landscape rich with scientific innovation, regulatory scrutiny, and strategic business decisions shaping the future of healthcare.Let's begin with Novartis, which has achieved a significant milestone by securing FDA approval for Itvisma. This is an intrathecal formulation of its gene therapy Zolgensma, designed to treat older patients ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful events and breakthroughs that are shaping patient care and drug development.The U.S. Food and Drug Administration recently granted early approval for a combination therapy using Padcev and Keytruda for the perioperative treatment of bladder cancer, a decision made months ahead of schedule. This approval represents a...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of significant stories shaping the future of healthcare, from innovative financing strategies to groundbreaking scientific advancements.The biotech industry in 2025 has experienced a notable shift in funding strategies, particularly through the rising trend of royalty financing. This approach, involving the exchange of future drug re...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. Thi...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, whic...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the industry, exploring significant scientific advancements, regulatory changes, clinical trial outcomes, and strategic investments that are shaping the future of healthcare.Starting with strategic investments, Regeneron is making a bold move with a $2 billion investment to transform a former magazine factory in Sara...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of pivotal changes and advancements that have been shaping our industry.The competitive nature of acquisitions within the biopharma sector has been exemplified by recent strategic buyouts. Lundbeck's decision to outbid Alkermes for Avadel Pharmaceuticals highlights how companies are leveraging acquisitions to expand their capabi...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several groundbreaking advancements and strategic shifts in the industry that promise to reshape the landscape of patient care and therapeutic innovations.The U.S. Food and Drug Administration has introduced a novel regulatory pathway aimed at expediting the approval process for custom gene-editing therapies. Articulated by FDA officials...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling updates that underscore the dynamic nature of our industry, marked by scientific breakthroughs, strategic shifts, regulatory advancements, and more.Starting with Pfizer's ambitious endeavors in oncology, the company has initiated Phase 3 trials for its bispecific antibody PF-08634404, targeting non-small cell lung canc...
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Met...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectab...
Comments
Download from Google Play
Download from App Store
United States